All articles tagged with #inflammatory bowel disease
Innovative Israeli technologies using engineered bacteria and wearable stress monitors aim to detect Crohn's disease flare-ups before symptoms appear, potentially transforming disease management by enabling earlier intervention and reducing complications.
A study shows that high consumption of soybean oil, rich in linoleic acid, can harm gut health by promoting harmful bacteria and weakening the intestinal barrier, potentially increasing the risk of inflammatory bowel disease; healthier fats like olive oil are recommended.
Inflammatory bowel disease (IBD), affecting up to 3.1 million adults in the U.S., is a chronic condition where the immune system attacks the intestines, causing inflammation and damage. Diagnosis involves medical history, physical exams, lab tests, and imaging like endoscopy or MRI. IBD differs from irritable bowel syndrome (IBS), which has similar symptoms but no underlying disease. Managing IBD requires a team approach to find effective medication and lifestyle strategies to prevent flare-ups and address related health issues.
Researchers at the University of Massachusetts Amherst have found that consuming strawberries can significantly reduce inflammation and symptoms of inflammatory bowel disease (IBD), which affects over 300,000 people in Britain. The study, led by Professor Hang Xiao, suggests that incorporating whole strawberries into the diet could improve gut health by reversing harmful gut bacteria and reducing colonic inflammation. The findings highlight the potential of dietary interventions in managing IBD, which is typically treated with surgery and medication.
Researchers at the Francis Crick Institute in London have discovered a key driver of inflammatory bowel disease (IBD) and other immune disorders, potentially leading to new treatments using existing drugs. This breakthrough could significantly impact the lives of millions suffering from conditions like Crohn's disease and ulcerative colitis.
Scientists at the Francis Crick Institute and University College London have discovered a "gene desert" in DNA linked to Inflammatory Bowel Disease (IBD), including Crohn's Disease. This genetic weak spot in white blood cells, which release inflammation-causing cytokines, appears in 95% of IBD patients. The discovery could lead to new treatments, including the use of existing MEK inhibitor drugs to reduce inflammation, potentially improving the lives of millions affected by IBD.
Scientists from University College London and the Francis Crick Institute have identified a genetic pathway that significantly contributes to inflammatory bowel disease (IBD), including Crohn's disease. By exploring a "gene desert," they discovered an enhancer that activates inflammation-related genes in macrophages. This breakthrough could lead to more effective treatments using existing drugs that target this pathway, offering new hope for IBD patients. The findings were published in Nature.
UK researchers have identified a genetic flaw linked to inflammatory bowel disease (IBD) that causes immune cells to attack the gut. This discovery, involving the ETS2 gene, could lead to new treatments, including repurposing existing autoimmune drugs. The findings, published in Nature, offer hope for better management and potential future cures for IBD.
UK scientists have identified a genetic weak spot present in 95% of people with inflammatory bowel disease (IBD), which causes immune cells to drive excessive inflammation in the bowels. Existing drugs have shown promise in reversing the disease in lab experiments, and researchers aim to start human trials within five years. This discovery could lead to new treatments for conditions like Crohn's disease and ulcerative colitis, which affect around half a million people in the UK.
Researchers at the Francis Crick Institute have identified a key biological pathway involved in inflammatory bowel disease (IBD) and other autoimmune disorders, which can be targeted by existing drugs. This discovery, described as a "holy grail," could lead to new treatments for conditions like Crohn's disease and ulcerative colitis. The team found that the ETS2 gene, regulated by a DNA enhancer in immune cells, plays a central role in the inflammation process. They are now working on adapting MEK inhibitors to specifically target macrophages, potentially offering a safer and more effective treatment option. Clinical trials are expected to begin soon.
Researchers at the Francis Crick Institute, UCL, and Imperial College London have identified a new biological pathway involving the gene ETS2 that drives inflammatory bowel disease (IBD). This discovery, published in Nature, reveals that existing MEK inhibitors can potentially reduce inflammation by targeting this pathway, offering hope for better treatments for IBD and related autoimmune conditions.
Michael Sheridan, diagnosed with ulcerative colitis in 2009, experienced a sudden flare-up in 2019, leading to a stage 3 colon cancer diagnosis in December 2020. After undergoing a sigmoidectomy and chemotherapy, he is now cancer-free. The experience prompted him to advocate for informed consent in his treatment and cherish time with his family. Inflammatory bowel disease patients should be vigilant about symptoms and undergo regular colonoscopies due to the increased risk of colorectal cancer.
Michael Sheridan, diagnosed with ulcerative colitis in 2009, experienced a sudden flare-up in 2019, leading to a stage 3 colon cancer diagnosis in December 2020. After undergoing a sigmoidectomy and chemotherapy, he is now cancer-free. His experience highlights the increasing incidence of colon cancer in young people, particularly those with inflammatory bowel disease, and the importance of regular colonoscopies for early detection.
Pfizer's drug Velsipity, used to treat ulcerative colitis, has been approved by the European Commission for patients aged 16 or older who did not respond well to previous treatments. The approval, based on successful late-stage trials, allows the drug to be available in all 27 EU countries. With an estimated 2.6 million people in Europe living with ulcerative colitis, Velsipity is expected to compete with Bristol Myers Squibb's Zeposia and has also sought regulatory approvals in other countries.
Researchers from Howard University presented a study suggesting that saffron supplements may reduce inflammation and improve clinical manifestations in people with ulcerative colitis. The study involved participants receiving low or high doses of saffron or a placebo for 8 weeks, with those taking high doses showing significant improvement in clinical scores and inflammatory biomarkers. Saffron also led to a decrease in harmful bacteria and an increase in beneficial bacteria in the gut. While promising, the use of saffron for IBD should be assessed on a case-by-case basis and may not be suitable for everyone.